Resumo

JARAMILLO GONZALEZ, Luis Eduardo et al. Treatment of Adult Schizophrenic Patients With Depot Antipsychotics. rev.colomb.psiquiatr. [online]. 2014, vol.43, suppl.1, pp.40-58. ISSN 0034-7450.  https://doi.org/10.1016/j.rcp.2015.05.005.

Objectives: To determine the indications of long-acting antipsychotic injection and what its effectiveness and safety in adult patients with schizophrenia during the treatment maintenance phase. Methods: A clinical practice guideline was elaborated under the parameters of the Methodological Guide of the Ministerio de Salud y Protección Social to identify, synthesize and evaluate the evidence and make recommendations about the treatment and follow-up of adult patients with schizophrenia. The evidence of NICE guide 82 was adopted and updated. The evidence was presented to the Guideline Developing Group and recommendations, employing the GRADE system, were produced. Results: The literature review shows that the evidence has moderate to low quality. 8 articles were used. The risk of relapse was lower with depot risperidone and paliperidone palmitate when compared with placebo. For the risk of hospitalizations comparing depot antipsychotics (APD) versus oral AP, the result is inconclusive. Globally the second-generation APD had a lower risk of discontinuation when compared with placebo. The second generation AP had higher risk of extrapyramidal syndromes than placebo, as in the use of antiparkinsonian. The comparison of second-generation AP injections versus placebo showed an increased risk of early weight gain. Conclusion: The use of depot antipsychotics in the maintenance phase of adult patients diagnosed with schizophrenia is recommended if there is no adherence to oral antipsychotics as the patient’s preference. It is not recommended depot antipsychotics in the acute phase of schizophrenia in adults.

Palavras-chave : Clinical Practice Guidelines; Schizophrenia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )